Abstract
Protein S is a natural anticoagulant. Congenital protein S (PS) deficiency is a confirmed risk factor of venous thromboembolism (DVT) which though occurs infrequently yet is a leading cause of maternal mortality and morbidity. Congenital PS deficiency may also be responsible for obstetric complications such as preeclampsia/eclampsia, recurrent fetal loss and intrauterine fetal restriction. Congenital PS deficiency has been identified in 1-7.5 % of patients with DVT and in 0.03-0.13 % general Caucasian population. However, Japanese people have higher prevalence both in VTE patients (12.7 %) and general population (0.48-0.63 %). Because PS deficiency is the most frequent congenital thrombophilia in Japanese people, Japanese obstetricians must understand this thrombophilia and also that women with PS deficiency have an increased risk of VTE and a necessity of prophylactic use of anticoagulant against recurrent VTE during pregnancy and puerperium. This article reviews the literature to understand PS and congenital PS deficiency, especially the association of this thrombophilia with pregnancy.
Keywords: protein s deficiency, venous thromboembolism, pregnancy, obstetric complications
Current Drug Targets
Title: Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese
Volume: 6 Issue: 5
Author(s): Tomoko Adachi
Affiliation:
Keywords: protein s deficiency, venous thromboembolism, pregnancy, obstetric complications
Abstract: Protein S is a natural anticoagulant. Congenital protein S (PS) deficiency is a confirmed risk factor of venous thromboembolism (DVT) which though occurs infrequently yet is a leading cause of maternal mortality and morbidity. Congenital PS deficiency may also be responsible for obstetric complications such as preeclampsia/eclampsia, recurrent fetal loss and intrauterine fetal restriction. Congenital PS deficiency has been identified in 1-7.5 % of patients with DVT and in 0.03-0.13 % general Caucasian population. However, Japanese people have higher prevalence both in VTE patients (12.7 %) and general population (0.48-0.63 %). Because PS deficiency is the most frequent congenital thrombophilia in Japanese people, Japanese obstetricians must understand this thrombophilia and also that women with PS deficiency have an increased risk of VTE and a necessity of prophylactic use of anticoagulant against recurrent VTE during pregnancy and puerperium. This article reviews the literature to understand PS and congenital PS deficiency, especially the association of this thrombophilia with pregnancy.
Export Options
About this article
Cite this article as:
Adachi Tomoko, Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese, Current Drug Targets 2005; 6 (5) . https://dx.doi.org/10.2174/1389450054545980
DOI https://dx.doi.org/10.2174/1389450054545980 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Current Cancer Drug Targets Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis
Current Pharmaceutical Design The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
Current Vascular Pharmacology Fondaparinux
Current Pharmaceutical Design Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets New Thrombin and Factor Xa Inhibitors for Primary and Secondary Prevention of Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews The Appearance of Middle Meningeal Artery Fistulae After Willis Covered Stent for Traumatic Carotid-cavernous Fistulae: Two Case Reports
Current Medical Imaging HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Stem Cells in Stroke Repair: Current Success & Future Prospects
CNS & Neurological Disorders - Drug Targets Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics The Vasculature as a Target in the Treatment of Pulmonary Emphysema
Current Drug Targets Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts
Current Cardiology Reviews